Genta, Aventis Halt Genasense Expanded Access Program
This article was originally published in The Pink Sheet Daily
Executive Summary
The Aventis-managed program was terminated following an FDA advisory committee’s negative review of the melanoma therapy and withdrawal of the NDA.
You may also be interested in...
Genta/Aventis To Meet With FDA After Genasense NDA Withdrawal
The meeting will review key issues and identify next steps for Genasense development, Genta said. The company expects to release data from Phase III melanoma and leukemia studies throughout the year.
Genta Stops Active Marketing Of Ganite
Genta stops actively marketing its cancer-related hypercalcemia treatment Ganite as part of company restructuring
Genasense Melanoma Progression-Free Survival Data Do Not Show "Real Effect," Cmte. Says
Committee votes 13 to 3 that substantial evidence of effectiveness has not been demonstrated for Aventis/Genta's Genasense in metastatic melanoma. FDA and committee cite concerns about the way progression-free survival and response data were collected.